Molzym develops solutions for molecular microbiology research and routine microbial pathogen diagnostics relied upon by leading hospitals and laboratories around the world. The company recently reported that several European and Asian centers have started a collaborative study to use the company’s Micro-Dx and SepsiTest-UMD diagnostic tests to identify co-infections in Covid-19-positive patients early on.
Molzym’s founder Michael Lorenz says the two companies “are a perfect match – we share the same values and pursue the same goals.” Being part of Gradian will allow Molzym to accelerate its growth and gain a foothold in the U.S. market, he adds. “Our customers will benefit, our staff will benefit, our current and new partners will benefit – a fantastic result all around.”
Gradian president Alex Malbran says the group’s goal “is to deliver best-in-class solutions that help hospitals and labs with the challenges and opportunities they face today and in the future.” With Molzym on board, he says, Gradian “is in a better position to improve molecular diagnosis for a broad range of customers.”